You can check out MYX complete products' catalogue here --->
Link
Mayne Pharma has total 30 products in pipeline targeting US market with sales over US$5bn.
It has 15 products pending at the FDA with a total market value of over US$2.5bn.
Company filed eight products with the FDA including its NDA for SUBA - itraconazole capsule, received FDA approval for five generic products and launched six generic products in the US.
In Australia, the Company launched two specialty brands products.
The most significant product in 2019 will be generic Nuvaring which
is an intra vaginal hormonal contraceptive delivery device combining etonogestrel and ethinyl estradiol over a 3-week period and that mean enjoy intercourse throughout the month with no restricted day! 
In March 2008, Mayne Pharma announced its Abbreviated New Drug Application (ANDA) for generic NuvaRing has been accepted for filing by the US Food and Drug Administration (FDA).
NuvaRing is the largest contraceptive sold in the
US$5.6 billion US contraceptive market with no generic equivalents today. Mayne Pharma expect to commercialise generic NuvaRing in FY19 and I’m predicting NuvaRing will itself initially generate revenue around US$500M as Merck's NuvaRing had total US sales of approximately US$830 million for the 12 months ending 31 January 2018.
View attachment 1272128
